| abstract |
A liver fibrosis inhibitor for use in the treatment of liver fibrosis by inhibiting the expression of naophen, which comprises as an effective ingredient a derivative of the hydroquinone compound represented by Formula (1): in which, R1 represents an alkyl group with a carbon number of 4 to 8, and R2 represents a hydrogen atom, an alkylcarbonyl group with a carbon number of 2 to 6, or an alkoxycarbonyl group with a carbon number of 2 to 6. |